<DOC>
	<DOCNO>NCT01034397</DOCNO>
	<brief_summary>This randomize , double-blind , placebo-controlled study use Magnetic Resonance Imaging ( MRI ) ass efficacy tocilizumab plus non-biological DMARD patient moderate severe rheumatoid arthritis inadequate response non-biological DMARDS . Patients randomize receive either intravenous tocilizumab 8mg/kg ( minimal dose 480mg , maximum dose 800mg ) placebo every 4 week , addition stable dose non-biological DMARD . Anticipated time study treatment 24 week , target sample size &lt; 100 .</brief_summary>
	<brief_title>A Study Tocilizumab Plus Non-biological DMARD Patients With Moderate Severe Rheumatoid Arthritis Inadequate Response Non-biological DMARDs</brief_title>
	<detailed_description />
	<mesh_term>Arthritis</mesh_term>
	<mesh_term>Arthritis , Rheumatoid</mesh_term>
	<mesh_term>Antirheumatic Agents</mesh_term>
	<criteria>adult patient , &gt; /=18 year age moderate severe rheumatoid arthritis &gt; /=6 month duration synovitis ( swollen tender joint ) wrist dominant hand nonbiologic DMARDs stable dose &gt; /=12 week prior baseline oral corticosteroid stable dose least 25 28 day prior baseline rheumatic autoimmune disease RA history current inflammatory joint disease RA functional class IV ( ACR classification ) intraarticular parenteral corticosteroid within 6 week prior baseline previous treatment biologic agent RA</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2015</verification_date>
</DOC>